Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Weight Loss

Retatrutide and tirzepatide are both Eli Lilly incretin-based investigational and approved obesity therapeutics, but they differ at the receptor pharmacology level — and that difference appears to translate into the largest weight-loss magnitudes published for any pharmacotherapy class to date. Tirzepatide is the current FDA-approved standard of care for chronic weight management; retatrutide represents the next generation but remains investigational as of April 2026.

Receptor Pharmacology

Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the glucagon-like peptide-1 (GLP-1) receptor — the same target as semaglutide — and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The combination of incretin signaling produces greater appetite suppression and metabolic benefit than GLP-1 monotherapy.

Retatrutide is a triple agonist of GLP-1, GIP, and the glucagon receptor. The addition of glucagon receptor agonism is the structural innovation. While glucagon's classical role is to raise blood glucose, controlled glucagon receptor activation also increases energy expenditure (via thermogenesis and increased basal metabolic rate) and shifts hepatic substrate utilization. The triple-agonist hypothesis is that GLP-1/GIP-mediated appetite suppression combined with glucagon-mediated energy expenditure produces additive weight loss beyond what dual agonists achieve.

Weight Loss Magnitude

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) reported mean weight loss of approximately 24.2% at 48 weeks on the 12 mg dose in adults with obesity — the largest mean weight loss reported for any obesity drug at that point. Phase 3 TRIUMPH-1 results published in December 2025 substantially confirmed this magnitude over 72 weeks. Tirzepatide produced a mean 22.5% body weight reduction at 72 weeks on the 15 mg dose in SURMOUNT-1.

The two drugs have not been compared head-to-head in a published RCT. The available data support a meaningfully greater mean weight-loss magnitude with retatrutide, though indirect cross-trial comparison must be interpreted with caution given different populations, durations, and analytic methods.

Regulatory Status

Tirzepatide is FDA-approved: Mounjaro (May 2022) for type 2 diabetes; Zepbound (November 2023) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. Retatrutide is investigational as of April 2026 — Phase 3 TRIUMPH program is ongoing, with anticipated FDA submission and possible approval in late 2026 or 2027 pending complete trial readouts.

Side Effect Profile

Both drugs share the GLP-1 class side-effect profile, dominated by gastrointestinal events (nausea, vomiting, diarrhea, constipation) most pronounced during dose escalation. Retatrutide's glucagon agonism introduces additional considerations: theoretical risk of glucose elevation (although in trials glycemic control improved overall, likely because GLP-1/GIP-mediated insulin and appetite effects dominate), and a higher reported incidence of certain dose-limiting adverse events compared with dual agonists. The FDA boxed warning for thyroid C-cell tumors applies to the GLP-1 class and is anticipated to apply to retatrutide based on class labeling precedent.

Cost and Access

Tirzepatide list price is approximately $1,000–$1,350 per month in the U.S., with insurance coverage growing but still variable for the obesity indication. Retatrutide pricing is not yet established because the drug is not commercially available; if approved, it would likely launch in a similar premium tier to tirzepatide. Both remain inaccessible to the global majority of people who could clinically benefit, an access issue that is part of the broader policy debate around incretin-class drugs.